Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1331, 2002-01, pp. : 8-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Pioglitazone economically attractive for type 2 DM in Canada
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 356, 2002-01 ,pp. :
Access to resources
Recommend
Pioglitazone the answer to managing type 2 DM in Europe?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 343, 2001-01 ,pp. :
Pioglitazone combination therapy good value in type 2 DM
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 450, 2004-01 ,pp. :
Potential HCV vaccine "highly economically attractive" in Canada
Inpharma, Vol. 1, Iss. 1477, 2005-01 ,pp. :
Pioglitazone improves measures of T2DM and dyslipidaemia
Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. :